Novozymes is a global leader in bioinnovation, producing industrial enzymes and microorganisms. It has over 700 products used in 130 countries across 40 industries. Novozymes has a diverse business portfolio including household care, food and beverages, bioenergy, and more. It invests heavily in R&D, with 14% of annual sales reinvested and over 5,800 patents granted or pending. Novozymes leverages its expertise and global market presence across segments to accelerate innovation and maintain its market leader position.
2. A growing global
population puts pressure
on our natural resources.
With bioinnovation in the
form of, for example,
industrial enzymes and
microorganisms, industries
can rethink their processes
and products, and produce
more with less.
2
3. Novozymes ā
The World Leader in Bioinnovation
ā¢ Business consists of two segments:
Enzyme Business and BioBusiness Founded 1941
ā¢ 2011 sales: USD ~ 2 billion Listed 2000
ā¢ 2011 EBIT margin: 22.3% Ticker NZYM B
Exchange Copenhagen
ā¢ More than 700 products used in 130
countries in over 40 different industries Market Cap* ~ 10 Billion USD
ā¢ ~ 7,000 granted and pending patents
ā¢ + 5,800 employees
ā¢ Two share classes; A and B shares
ā¢ A share capital and 11% of B shares
(25.5% of O/S; 70.1% of votes) held by
Enzyme Business BioBusiness
Novo A/S, the management company of
the Novo Nordisk Foundation
Household Food & Feed & Micro-
Bioenergy Biopharma
Care Beverages other Tech. organisms
*A+B shares January, 2012
3
4. Uniquely Diversified Group Creates Synergies and
New Opportunities
ā¢ Unique biotech-focused business with a strong legacy of delivering growth, earnings, and cash flow
ā¢ ~ 14% of annual sales invested in R&D
ā¢ Global provider of enzymes to all market segments creates global market leader position
ā¢ Leveraging competencies across segments accelerates pace of innovation, reduces competition and creates
high barriers to entry
31% 29% 17% 13% 7% 3%
Household Food & Bioenergy Feed & other Micro- Biopharma
Care Beverages Technical organisms
enzymes
ā¢ Laundry & ā¢ Baking ā¢ Corn ethanol ā¢ Animal feed ā¢ BioAgriculture ā¢ Drug delivery &
Dishwasher ā¢ Brewing ā¢ Cellulosic ā¢ Textile ā¢ Wastewater formulation
detergents ā¢ Starch to biofuels ā¢ Leather ā¢ Institutional ā¢ Medical devices
syrups ā¢ Pulp & Paper & household
ā¢ Wine & juice cleaning
Enzyme Business BioBusiness
4
5. Diversification in Revenue Streams Underpins
the Companyās Strong Financial Position
ā¢ Enzymes account for 90% of turnover
ā¢ Sales FY 2011 of DKK 10,510 billion (USD ~ 2 billion)
ā¢ Strong profitability, ~ 22% in EBIT margin FY 2011
ā¢ ROIC of ~ 21% for FY 2011
2011 Sales by geography 2011 Sales by industry
Biopharma
Microorga
3%
nisms
Feed &
7%
other
Latin Tech.
America enzymes
10% Europe, 13%
Household
Middle
Asia Care
East and
Pacific enzymes
Africa
19% 31%
36%
Bioenergy
enzymes
19%
Food &
North Beverages
America enzymes
35% 29%
5
6. Undisputed Market Leader
Expanding Enzyme Application
Global enzyme market value:
2000: 2011: Global enzyme market value
DKK ~ 12bn DKK ~ 20bn 2011: DKK ~ 20bn
Novozymes Rest of Novozymes
Rest of 47% Others and
42% market
market
53% captive
58%
26%
Novozymes
47%
DSM
6%
Market potential*
Genencor
Current enzyme market (DuPont)
DKK ~ 20bn 21%
Untapped market
Multi-billion (US$)
Rules of competition
dictated by innovation
*Global markets for chemicals, food ingredients, feed additives, etc.
6
7. R&D on the geographical map
- 9 global competence centers / 1000 employees
105 employees 30 employees 553 employees
ļ§ Strain dev. ļ§ Pharma center ļ§ All basic technologies
ļ§ Bioinformatics ļ§ Albumin and ļ§ All application
ļ§ Protein Engineering Albufusion technologies except
ļ§ Protein Chemistry ļ§ Patent and regulatory textile
ļ§ Biomass ļ§ Patent and regulatory
37 employees
ļ§ Metabolic Engineering ļ§ Strain development
ļ§ Patent ļ§ Protein Engineering
ļ§ New applications
ļ§ Regulatory
58 Employees
ļ§ Strain discovery
ļ§ Microbial physiology
of mixed cultures
ļ§ Microbial ecology
ļ§ Microbe application
expertise within
technical microbes &
BioAg
77 employees
66 employees ļ§ Fungal screening
ļ§ Biofuel
27 employees ļ§ New applications
ļ§ New Industries ļ§ Protein Engineering ļ§ Detergents
ļ§ Renewal of chemicals ļ§ Protein Chemistry ļ§ Textiles
7employees ļ§ Application dev. W&J ļ§ Biomass
ļ§ Patent and Regulatory
ļ§ Biofuel ļ§ Surface fermentation ļ§ Patent and Regulatory
8. From gene-bank to product in 12 months
Technologies Process
Individual shuffling
Family shuffling
Creating Biological Natureās diversity
Diversity
Bioinformatics Molecular evolution
Mega libraries (int. and ext.)
1Ā° Screening
Protein Engineering
Screening technology
2Ā° Screening
ā¢High throughput screening: Microbial
and Molecular level
ā¢Targeted assay
Creating
Expression
Expression (bacterial, fungal)
System
Fermentation
Up-scaling
Process Purification
Lab fermentation
Pilot and tox material Production
Formulation
Full scale application test
Biosolution based on Novozymes Technology
9. Novozymes, Inc
Our key core technologies
NZCA: today cover:
ļ§ Established in 1992
ļ§ Located in Davis, CA ļ§System Biology, Genomics &
ļ§ 45% males : 55 % females Bioinformatics
ļ§ We have around 110 FTE ļ§Fungal & Bacterial Expression
ļ§ Average seniority: 8 years Technology
ļ§ Historically we file 12-25
ļ§Metabolic engineering
patents/year
ļ§Microbial Physiology &
Fermentation
ļ§Robotics, Assay Technology & HTS
ļ§Protein Chemistry
ļ§Artificial evolution
10. 10
Significant achievements
CTec1 and CTec2 incl. discovery of GH61
Numerous improved production strains and molecular tools
ā¢ Savinase, Polarzyme, Everlase, Pullulanase, Novamyl
ā¢ Improved promoters, genomic loci for expression
Genome sequencing and systems biology
ā¢ Sequencing the genomes of more than 30 NZ organisms; host strains and BioAg
strains incl. collaboration with JGI on T. reesei TV10
ā¢ Developed technology to identify specific nucleotide changes conferring improved
yields in Bacillus strains
Metabolic engineering
ā¢ HA-strain development
ā¢ CoRe projects established and running with 3 major partners: Cargill (3-HP), ADM,
Braskem (Green PP)